VRTX241101P280000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Vertex Pharmaceuticals Analyst Ratings
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Oppenheimer Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $540
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $555
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Cuts Target Price to $361
Scotiabank Initiates Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Announces Target Price $480
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Vertex Pharmaceuticals (VRTX) Gets a Buy From Truist Financial
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $509
Vertex Pharmaceuticals: Hold Rating Amid Promising Developments and Pending Long-Term Validation
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $535
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
Vertex Pharmaceuticals' Promising Market Position and Opioid-Sparing Solution Drive Buy Rating
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
Optimistic Buy Rating for Vertex Pharmaceuticals Amid Promising VX-548 Developments
Vertex Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)